Prospective study of hepatitis B virus reactivation in patients with hematological malignancies

Annals of Hepatology

Volumn 14, Issue 2, 2015, Pages 168-174

  Pompili, Maurizio ^a   Basso, Maria ^a   Hohaus, Stefan ^a   Bosco, Giulia ^a   Nosotti, Lorenzo ^b   D’Andrea, Mariella ^b   Fenu, Susanna ^c   Grieco, Antonio ^a   Laurenti, Luca ^a   Mirisola, Concetta ^b   Pagano, Livio ^a   Rapaccini, Gian Ludovico ^a   Sica, Simona ^a   Storti, Sergio ^a   Landolfi, Raffaele ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

Author keywords

Hematological malignancies; Hepatitis B virus reactivation; Immunosuppression; Resolved hepatitis B virus infection; Reverse seroconversion

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; RITUXIMAB; VIRUS DNA; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME; VIREMIA; VIRUS REACTIVATION; ADVERSE EFFECTS; BLOOD; GENETICS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED; PATHOGENICITY; RECURRENT DISEASE; RISK FACTOR; TIME; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84922621137     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30778-1     Document Type: Article

References (22)

1. Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 2012; 156: 743-5.
2. Marinone C, Mestriner M. HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis 2011; 43: S49-S56.
3. Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 9: 554-7.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2009; 50: 1-36.
5. EASL (European Association For The Study Of The Liver) clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
6. Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int 2011; 31: 104-10.
7. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini- Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34: 194-203.
8. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43: 209-20.
9. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
10. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
11. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712.
12. Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, Cameron S, et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol 2008; 41: 243-54.
13. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, et al. Kinetics and risk of de novo hepatitis B infection in HbsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
14. Inuzuka T, Ueda Y, Morimura H, Fujii Y, Umeda M, Kou T, Osaki Y, et al. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. J Hepatol 2014 May 2. pii: S0168-8278(14)00296-7. doi: 10.1016/ j.jhep.2014.04.033 [Epub ahead of print].
15. Viganò M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 125-31.
16. Tamori A, Hino M, Kawamura E, Fujii H, Uchida-Kobayashi S, Morikawa H, Nakamae H, et al. A prospective longterm study of hepatitis B virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol 2014 Apr 14. doi: 10.1111/jgh.12604 [Epub ahead of print].
17. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1049-59.
18. Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 809-17.
19. Ceneli O, Ozkurt ZN, Acar K, Rota S, Aki SZ, Yegin ZA, Yagci M, et al. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol 2010. 16:1765-1771.
20. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20: 2013-7.
21. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90: 1219-23.
22. Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012; 91: 1007-12.